BidaskClub lowered shares of Keryx Biopharmaceuticals (NASDAQ:KERX) from a sell rating to a strong sell rating in a report released on Thursday, September 13th.

KERX has been the topic of several other reports. HC Wainwright set a $9.00 price target on shares of Keryx Biopharmaceuticals and gave the company a buy rating in a research note on Thursday, August 23rd. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a sell rating to a hold rating in a research report on Monday, September 10th. Maxim Group cut shares of Keryx Biopharmaceuticals from a buy rating to a hold rating in a research report on Thursday, June 28th. Stifel Nicolaus reissued a hold rating and issued a $5.00 target price on shares of Keryx Biopharmaceuticals in a report on Monday, June 25th. Finally, ValuEngine raised shares of Keryx Biopharmaceuticals from a sell rating to a hold rating in a report on Thursday, June 21st. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $6.25.

NASDAQ KERX remained flat at $$3.20 on Thursday. 433,321 shares of the company’s stock traded hands, compared to its average volume of 1,122,010. Keryx Biopharmaceuticals has a 1 year low of $2.78 and a 1 year high of $8.07. The company has a market capitalization of $409.56 million, a price-to-earnings ratio of -3.64 and a beta of 2.44. The company has a debt-to-equity ratio of -3.16, a current ratio of 2.28 and a quick ratio of 1.40.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02). As a group, sell-side analysts expect that Keryx Biopharmaceuticals will post -0.61 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. grew its position in shares of Keryx Biopharmaceuticals by 3.4% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 536,951 shares of the biopharmaceutical company’s stock worth $2,197,000 after buying an additional 17,620 shares during the period. Swiss National Bank raised its stake in shares of Keryx Biopharmaceuticals by 13.0% during the 1st quarter. Swiss National Bank now owns 160,600 shares of the biopharmaceutical company’s stock worth $657,000 after purchasing an additional 18,500 shares during the period. Shufro Rose & Co. LLC raised its stake in shares of Keryx Biopharmaceuticals by 26.1% during the 2nd quarter. Shufro Rose & Co. LLC now owns 91,800 shares of the biopharmaceutical company’s stock worth $345,000 after purchasing an additional 19,000 shares during the period. Boston Partners raised its stake in shares of Keryx Biopharmaceuticals by 14.2% during the 2nd quarter. Boston Partners now owns 293,104 shares of the biopharmaceutical company’s stock worth $1,102,000 after purchasing an additional 36,544 shares during the period. Finally, Russell Investments Group Ltd. bought a new stake in shares of Keryx Biopharmaceuticals during the 1st quarter worth $201,000. 59.52% of the stock is owned by institutional investors.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Featured Article: Hedge Funds Explained

Analyst Recommendations for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.